# Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

> **NCT01014351** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 70 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01014351
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-02
- **Final completion:** 2013-08
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2014-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01014351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01014351, "Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT01014351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*